Roche Garners Rights to Repare's ATR Inhibitor for $125M Upfront

Retrieved on: 2022-06-02 18:19:05

Tags for this article:

Click the tags to see associated articles and topics

Roche Garners Rights to Repare's ATR Inhibitor for $125M Upfront. View article details on hiswai:

Excerpt

NEW YORK – Roche and Repare Therapeutics on Wednesday announced a global license agreement to develop and market Repare's ATR inhibitor ...

Article found on: www.precisiononcologynews.com